US Soldiers to Receive Psychedelic Therapy for PTSD

The Psychedelic Therapy Trials

The US Department of Defense (DoD) is funding two studies into psychedelic therapy for active-duty soldiers with PTSD. The studies, which will involve 186 service personnel, will investigate the use of MDMA-assisted therapy to help soldiers process trauma and reduce symptoms of PTSD.

The Research Details

The studies will be conducted at the Walter Reed national military medical center and Emory University, with the goal of determining the safety and efficacy of MDMA-assisted therapy for soldiers with PTSD. The therapy involves multiple sessions of MDMA-assisted therapy, with the aim of helping soldiers process trauma and reduce symptoms of PTSD.

The Data Analysis

The studies will involve a total of 186 service personnel, with 91 military, guard, and reserve personnel set to receive three separate MDMA doses across 10 months at Walter Reed. The studies are expected to cost $4.9m each, with the funding signed off by former president Joe Biden as part of the National Defence Authorization Act in December 2023.

The Impact Analysis

The use of psychedelic therapy for soldiers with PTSD has the potential to revolutionize the way that the military approaches mental health. According to Rick Doblin, the founding president of the Multidisciplinary Association for Psychedelic Studies (Maps), "Helping people process trauma, whoever they are, is probably better than not." The therapy could also help to reduce the stigma surrounding mental health issues in the military.

The Prediction

If the studies are successful, MDMA-assisted therapy could become a standard treatment for soldiers with PTSD. The therapy could also have implications for the treatment of PTSD in civilians, and could potentially be used to address other mental health issues. However, there are also concerns about the potential risks of using psychedelic therapy, particularly in an active-duty setting.